Germline TP53 Variants and Susceptibility to Osteosarcoma

Journal of the National Cancer Institute

Volumn 107, Issue 7, 2015, Pages

  Mirabello, Lisa ^a   Yeager, Meredith ^b   Mai, Phuong L ^a   Gastier Foster, Julie M ^c   Gorlick, Richard ^d   Khanna, Chand ^a   Patiño Garcia, Ana ^e   Sierrasesúmaga, Luis ^e   Lecanda, Fernando ^e   Andrulis, Irene L ^f   Wunder, Jay S ^f   Gokgoz, Nalan ^f   Barkauskas, Donald A ^g   Zhang, Xijun ^b   Vogt, Aurelie ^b   Jones, Kristine ^b   Boland, Joseph F ^b   Chanock, Stephen J ^a   Savage, Sharon A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^e UNIVERSITY CLINIC OF NAVARRA   (Spain)

^f MOUNT SINAI HOSPITAL   (Canada)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CHILD; EXON; FAMILIAL CANCER; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GERMLINE MUTATION; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MUTATION RATE; MUTATIONAL ANALYSIS; OSTEOSARCOMA; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE; BONE TUMOR; FEMALE; GENETIC PREDISPOSITION; GENETICS; MALE; ONSET AGE;

PROTEIN P53; TP53 PROTEIN, HUMAN;

ADULT; AGE OF ONSET; BONE NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; LI-FRAUMENI SYNDROME; MALE; OSTEOSARCOMA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84938099717     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv101     Document Type: Article

References (38)

1. Mirabello L, Troisi R, Savage S. Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115(7):1531-1543.
2. Mirabello L, Troisi R, Savage S. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer. 2009;125(1):229-234.
3. Ron E. Cancer risks from medical radiation. Health Phys. 2003;85:47-59.
4. Mirabello L, Pfeiffer R, Murphy G, et al. Height at diagnosis and birth-weight as risk factors for osteosarcoma. Cancer Causes Control. 2011;22(6):899-908.
5. Savage SA, Mirabello L, Wang Z, et al. Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet. 2013;45(7):799-803.
6. Savage S, Mirabello L. Using epidemiology and genomics to understand osteosarcoma etiology. Sarcoma. 2011;2011:548151.
7. Musselman J, Bergemann T, Ross J, et al. Case-parent analysis of variation in pubertal hormone genes and pediatric osteosarcoma: A Children's Oncology Group (COG) study. Int J Mol Epidemiol Genet. 2012;3(4):286-293.
8. Calvert GT, Randall RL, Jones KB, Cannon-Albright L, Lessnick S, Schiffman JD. At-Risk Populations for Osteosarcoma: The Syndromes and Beyond. Sarcoma. 2012;2012:9.
9. Li F, Fraumeni JJ. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med. 1969;71(4):747-752.
10. Li F, Fraumeni JJ. Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst. 1969;43(6):1365-1373.
11. Olivier M, Goldgar D, Sodha N, et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res. 2003;63(20):6643-6650.
12. Malkin D. Li-fraumeni syndrome. Genes Cancer. 2011;2(4):475-484.
13. Ognjanovic S, Olivier M, Bergemann T, Hainaut P. Sarcomas in TP53 germline mutation carriers: A review of the IARC TP53 database. Cancer. 2012;118(5):1387-1396.
14. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010;2(1):a001008.
15. Li F, Fraumeni J Jr, Mulvihill J, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988;48(18):5358-5362.
16. Tinat J, Bougeard G, Baert-Desurmont S, et al. 2009 Version of the Chompret Criteria for Li Fraumeni Syndrome. J Clin Oncol. 2009;27(26):e108-e109.
17. Chompret A, Abel A, Stoppa-Lyonnet D, et al. Sensitivity and predictive value of criteria for p53germline mutation screening. J Med Genet. 2001;38(1):43-47.
18. McIntyre JF, Smith-Sorensen B, Friend SH, et al. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J Clin Oncol. 1994;12(5):925-930.
19. Toguchida J, Yamaguchi T, Dayton SH, et al. Prevalence and Spectrum of Germline Mutations of the p53 Gene among Patients with Sarcoma. New Engl J Med. 1992;326(20):1301-1308.
20. Savage SA, Burdett L, Troisi R, Douglass C, Hoover RN, Chanock SJ. Germ-line genetic variation of TP53 in osteosarcoma. Pediatr Blood Cancer. 2007;49:28-33.
21. Toffoli G, Biason P, Russo A, et al. Effect of TP53 Arg72Pro and MDM2 SNP309 Polymorphisms on the Risk of High-Grade Osteosarcoma Development and Survival. Clin Cancer Res. 2009;15(10):3550-3556.
22. Gokgoz N, Wunder J, Mousses S, Eskandarian S, Bell R, Andrulis I. Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma. Cancer. 2001;92(8):2181-2189.
23. Pakos E, Kyzas P, Ioannidis J. Prognostic significance of TP53 tumor suppressor gene expression and mutations in human osteosarcoma: A meta-analysis. Clin Cancer Res. 2004;10(18 Pt 1):6208-6214.
24. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28:622-629.
25. Kato S, Han S-Y, Liu W, et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A. 2003;100(14):8424-8429.
26. Li X, Dumont P, Pietra AD, Shetler C, Murphy ME. The Codon 47 Polymorphism in p53 Is Functionally Significant. J Biol Chem. 2005;280(25):24245- 24251.
27. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Meth. 2010;7(4):248-249.
28. Schwarz JM, Rodelsperger C, Schuelke M, Seelow D. MutationTaster evaluates disease-causing potential of sequence alterations. Nat Meth. 2010;7(8):575- 576.
29. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protocols. 2009;4(8):1073-1081.
30. A map of human genome variation from population-scale sequencing. Nature. 2010;467(7319):1061-1073.
31. Grambsch P, Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515-526.
32. Diller L, Sexsmith E, Gottlieb A, Li FP, Malkin D. Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J Clin Invest. 1995;95(4):1606-1611.
33. Hwang S-J, Lozano G, Amos CI, Strong LC. Germline p53 Mutations in a Cohort with Childhood Sarcoma: Sex Differences in Cancer Risk. Am J Hum Genet. 2003;72(4):975-983.
34. Ognjanovic S, Olivier M, Bergemann TL, Hainaut P. Sarcomas in TP53 germline mutation carriers. Cancer. 2012;118(5):1387-1396.
35. Carraro DM, Koike Folgueira MAA, Garcia Lisboa BC, et al. Comprehensive Analysis of BRCA1, BRCA2 and TP53 Germline Mutation and Tumor Characterization: A Portrait of Early-Onset Breast Cancer in Brazil. PLoS ONE. 2013;8(3):e57581.
36. Lee D, Yoon S-Y, Looi L, et al. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients. Breast Cancer Res. 2012;14(2):R66.
37. Mouchawar J, Korch C, Byers T, et al. Population-Based Estimate of the Contribution of TP53 Mutations to Subgroups of Early-Onset Breast Cancer: Australian Breast Cancer Family Study. Cancer Res. 2010;70(12):4795-4800.
38. Villani A, Tabori U, Schiffman J, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: A prospective observational study. Lancet Oncol. 2011;12(6):559-567.